Login to Your Account

Northwest Biotherapeutics Seeks Antigen Deal To Avoid Folding

By Randall Osborne

Monday, November 11, 2002
About one month after saying it would suspend recruitment in a Phase III trial of its lead prostate cancer drug, sell some fixed assets and consider other options for the future, Northwest Biotherapeutics Inc. has made more cuts and may shut down entirely. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription